{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"38.0","upperLimit":"65.3","value":"51.8"},{"groupId":"OG001","lowerLimit":"28.6","upperLimit":"55.1","value":"41.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"56"},{"groupId":"OG001","value":"58"}],"units":"Participants"}],"description":"Response will be determined by a blinded centralized review of volumetric MRI. The confirmed objective response rate (complete or partial response) by the end of Treatment Phase (i.e., Cycle 24) is defined as the proportion of participants who have a confirmed ≥ 20% reduction in target tumor volume as compared to baseline as assessed by a BICR, and the response needs to be confirmed by BICR in a consecutive tumor assessment within 2 - 6 months. Partial response is defined as a ≥ 20% reduction in target tumor volume from baseline. Complete response is defined as the complete resolution of the target tumor.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients aged 2 to 17 years old at the time of informed consent. Mirdametinib (PD-0325901) capsule or dispersible tablet 2 mg/m\\^2 (maximum dose of 4 mg) by mouth twice daily","id":"OG000","title":"Treatment Phase - Pediatric Cohort Mirdametinib (PD-0325901)"},{"description":"Patients aged 18 and above at the time of informed consent. Mirdametinib (PD-0325901) capsule or dispersible tablet 2 mg/m\\^2 (maximum dose of 4 mg) by mouth twice daily","id":"OG001","title":"Treatment Phase - Adult Cohort Mirdametinib (PD-0325901)"}],"paramType":"NUMBER","populationDescription":"The Full Analysis Set is defined as patients who received at least one dose of Mirdametinib.","reportingStatus":"POSTED","timeFrame":"Up to 24 months","title":"Confirmed Objective Response Rate at the End of the Treatment Phase.","type":"PRIMARY","unitOfMeasure":"percentage of patients"}